mediarelease

BOUDRY, Switzerland–(BUSINESS WIRE)–Nov. 11, 2008–Celgene
International Sarl (NASDAQ: CELG) today announced that clinical
investigators from leading hematology research centers around the
world will present data from recent and on-going clinical trials of
multiple Celgene products at the 50th Annual American Society of
Hematology Meeting and Exposition from December 6-9, 2008 in San
Francisco, California. Nearly 130 posters […]

— Committee for Medicinal Products for Human Use (CHMP)
recommends approval of VIDAZA for treatment of MDS and AML

— First and only medicinal product to demonstrate significantly
extended survival for patients with higher risk
myelodysplastic syndromes (MDS)

— First medicinal product to achieve a transfusion independence
rate of greater than 40 percent across higher risk MDS
International Prognostic Scoring System (IPSS) risk categories

Innovative Trocar Line Features Proprietary Technology that Delivers a Range of Clinical Benefits

First and Only Self-Gripping, Easy-To-Use Repair System for Inguinal Hernias

Sprayable hydrogel technology offers surgeons a valuable tool to help reduce the incidence, severity and extent of post-surgical adhesions

Aptuit INDiGO(TM) accelerates drug development from pre-clinical candidate selection to regulatory filing on a fixed timeline and price

CHALFONT ST. GILES, England–(BUSINESS WIRE)–Sept. 30, 2008–GE
Healthcare, a unit of General Electric Company (NYSE:GE), today
announced it has acquired MicroCal LLC, a provider of innovative
instruments for the study of molecular interactions in pharmaceutical,
biomedical and life science research. The acquisition of MicroCal will
allow GE Healthcare to expand its offering of technologies for the
rapidly growing areas of protein […]

BOUDRY, Switzerland–(BUSINESS WIRE)–Sept. 15, 2008–Celgene
International Sarl (Nasdaq: CELG) today announced physicians from
leading international medical centers presented data from a Phase II
clinical study of Amrubicin in patients with extensive-disease
small-cell lung cancer (SCLC) sensitive to platinum-based first-line
therapy. Preliminary results of the study demonstrated an improved
overall response rate that compare favorably with topotecan, as […]

Study data show longer term efficacy and safety and tolerability
profile of sitagliptin up to two years

— Investigational study of sitagliptin and metformin as initial
combination therapy demonstrated substantial efficacy over two
years(1)

— Pooled analysis of 6,139 patients shows sitagliptin 100 mg a
day was generally well tolerated in clinical trials of up to
two years in duration(2)

— Investigational study of the addition of sitagliptin to the
combination of metformin and rosiglitazone substantially
improved blood sugar control(3*)

— 52-week study of Japanese patients with an investigational
dosing regimen demonstrated treatment with sitagliptin added
to ongoing pioglitazone therapy also provided powerful
glycaemic control(4)

— Additional analysis demonstrated that in patients with type 2
diabetes, sitagliptin provided effective and consistent
glycaemic control regardless of baseline characteristics of
age, gender, BMI, HOMA-(beta), and P/I ratio(5)

Data on SUTENT(R) and Investigational Agent CP-751,871 Will be Presented at the 33rd ESMO Congress